A citation-based method for searching scientific literature


List of co-cited articles
228 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.
Scott D Solomon, Michael Zile, Burkert Pieske, Adriaan Voors, Amil Shah, Elisabeth Kraigher-Krainer, Victor Shi, Toni Bransford, Madoka Takeuchi, Jianjian Gong,[...]. Lancet 2012
775
40

Angiotensin-neprilysin inhibition versus enalapril in heart failure.
John J V McMurray, Milton Packer, Akshay S Desai, Jianjian Gong, Martin P Lefkowitz, Adel R Rizkala, Jean L Rouleau, Victor C Shi, Scott D Solomon, Karl Swedberg,[...]. N Engl J Med 2014
34

Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial.
J L Rouleau, M A Pfeffer, D J Stewart, D Isaac, F Sestier, E K Kerut, C B Porter, G Proulx, C Qian, A J Block. Lancet 2000
324
31

Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE).
Milton Packer, Robert M Califf, Marvin A Konstam, Henry Krum, John J McMurray, Jean-Lucien Rouleau, Karl Swedberg. Circulation 2002
473
31

Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial.
John B Kostis, Milton Packer, Henry R Black, Roland Schmieder, David Henry, Elliott Levy. Am J Hypertens 2004
374
31


Natriuretic peptides.
E R Levin, D G Gardner, W K Samson. N Engl J Med 1998
28

Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).
Jessie Gu, Adele Noe, Priya Chandra, Suliman Al-Fayoumi, Monica Ligueros-Saylan, Ramesh Sarangapani, Suzanne Maahs, Gary Ksander, Dean F Rigel, Arco Y Jeng,[...]. J Clin Pharmacol 2010
354
22

Plasma bradykinin in angio-oedema.
J Nussberger, M Cugno, C Amstutz, M Cicardi, A Pellacani, A Agostoni. Lancet 1998
557
20

Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics.
Sarah Mangiafico, Lisa C Costello-Boerrigter, Ingrid A Andersen, Alessandro Cataliotti, John C Burnett. Eur Heart J 2013
167
20

Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study.
Kazuomi Kario, Ningling Sun, Fu-Tien Chiang, Ouppatham Supasyndh, Sang Hong Baek, Akiko Inubushi-Molessa, Ying Zhang, Hiromi Gotou, Martin Lefkowitz, Jack Zhang. Hypertension 2014
151
20

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC.
John J V McMurray, Stamatis Adamopoulos, Stefan D Anker, Angelo Auricchio, Michael Böhm, Kenneth Dickstein, Volkmar Falk, Gerasimos Filippatos, Cândida Fonseca, Miguel Angel Gomez-Sanchez,[...]. Eur Heart J 2012
20

Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II.
A M Richards, G A Wittert, I G Crozier, E A Espiner, T G Yandle, H Ikram, C Frampton. J Hypertens 1993
121
17




Vasopeptidase inhibition and angio-oedema.
F H Messerli, J Nussberger. Lancet 2000
176
17

Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?
R Corti, J C Burnett, J L Rouleau, F Ruschitzka, T F Lüscher. Circulation 2001
166
14

Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure.
Thomas G von Lueder, S Jeson Sangaralingham, Bing H Wang, Andrew R Kompa, Dan Atar, John C Burnett, Henry Krum. Circ Heart Fail 2013
99
14

Therapy of heart failure.
R W Schrier, J G Abdallah, H H Weinberger, W T Abraham. Kidney Int 2000
33
15

Recent advances in natriuretic peptides in congestive heart failure.
Guido Boerrigter, John C Burnett. Expert Opin Investig Drugs 2004
65
14

Effect of nesiritide in patients with acute decompensated heart failure.
C M O'Connor, R C Starling, A F Hernandez, P W Armstrong, K Dickstein, V Hasselblad, G M Heizer, M Komajda, B M Massie, J J V McMurray,[...]. N Engl J Med 2011
869
14

2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
Clyde W Yancy, Mariell Jessup, Biykem Bozkurt, Javed Butler, Donald E Casey, Mark H Drazner, Gregg C Fonarow, Stephen A Geraci, Tamara Horwich, James L Januzzi,[...]. J Am Coll Cardiol 2013
14

Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions.
Lincoln R Potter, Sarah Abbey-Hosch, Deborah M Dickey. Endocr Rev 2006
700
14

Crystal structure of the human angiotensin-converting enzyme-lisinopril complex.
Ramanathan Natesh, Sylva L U Schwager, Edward D Sturrock, K Ravi Acharya. Nature 2003
473
14

RXP 407, a phosphinic peptide, is a potent inhibitor of angiotensin I converting enzyme able to differentiate between its two active sites.
V Dive, J Cotton, A Yiotakis, A Michaud, S Vassiliou, J Jiracek, G Vazeux, M T Chauvet, P Cuniasse, P Corvol. Proc Natl Acad Sci U S A 1999
133
14

Ace revisited: a new target for structure-based drug design.
K Ravi Acharya, Edward D Sturrock, James F Riordan, Mario R W Ehlers. Nat Rev Drug Discov 2003
199
14

Fragment-based design for the development of N-domain-selective angiotensin-1-converting enzyme inhibitors.
Ross G Douglas, Rajni K Sharma, Geoffrey Masuyer, Lizelle Lubbe, Ismael Zamora, K Ravi Acharya, Kelly Chibale, Edward D Sturrock. Clin Sci (Lond) 2014
25
20

Selective inhibition of the C-domain of angiotensin I converting enzyme by bradykinin potentiating peptides.
Joël Cotton, Mirian A F Hayashi, Philippe Cuniasse, Gilles Vazeux, Danielle Ianzer, Antonio C M De Camargo, Vincent Dive. Biochemistry 2002
64
14


Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.
Salim Yusuf, Bertram Pitt, Clarence E Davis, William B Hood, Jay N Cohn. N Engl J Med 1991
11


Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure.
Jonathan D Sackner-Bernstein, Hal A Skopicki, Keith D Aaronson. Circulation 2005
550
11

Human hypertension is characterized by a lack of activation of the antihypertensive cardiac hormones ANP and BNP.
Fima Macheret, Denise Heublein, Lisa C Costello-Boerrigter, Guido Boerrigter, Paul McKie, Diego Bellavia, Sarah Mangiafico, Yasuhiro Ikeda, Kent Bailey, Christopher G Scott,[...]. J Am Coll Cardiol 2012
71
11

Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases.
Speranza Rubattu, Sebastiano Sciarretta, Valentina Valenti, Rosita Stanzione, Massimo Volpe. Am J Hypertens 2008
147
11

Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema.
R M Fryer, J Segreti, P N Banfor, D L Widomski, B J Backes, C W Lin, S J Ballaron, B F Cox, J M Trevillyan, G A Reinhart,[...]. Br J Pharmacol 2008
100
11


Biology of the natriuretic peptides.
Abelardo Martinez-Rumayor, A Mark Richards, John C Burnett, James L Januzzi. Am J Cardiol 2008
161
11


Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.
Milton Packer, John J V McMurray, Akshay S Desai, Jianjian Gong, Martin P Lefkowitz, Adel R Rizkala, Jean L Rouleau, Victor C Shi, Scott D Solomon, Karl Swedberg,[...]. Circulation 2015
447
11


Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure.
Orly Vardeny, Ryan Miller, Scott D Solomon. JACC Heart Fail 2014
117
11


Role of the N-terminal catalytic domain of angiotensin-converting enzyme investigated by targeted inactivation in mice.
Sebastien Fuchs, Hong D Xiao, Justin M Cole, Jonathan W Adams, Kristen Frenzel, Annie Michaud, Hui Zhao, George Keshelava, Mario R Capecchi, Pierre Corvol,[...]. J Biol Chem 2004
79
11


The Dynamic Nonprime Binding of Sampatrilat to the C-Domain of Angiotensin-Converting Enzyme.
Rajni K Sharma, Marlene Espinoza-Moraga, Horacio Poblete, Ross G Douglas, Edward D Sturrock, Julio Caballero, Kelly Chibale. J Chem Inf Model 2016
9
44

The N domain of human angiotensin-I-converting enzyme: the role of N-glycosylation and the crystal structure in complex with an N domain-specific phosphinic inhibitor, RXP407.
Colin S Anthony, Hazel R Corradi, Sylva L U Schwager, Pierre Redelinghuys, Dimitris Georgiadis, Vincent Dive, K Ravi Acharya, Edward D Sturrock. J Biol Chem 2010
52
11

Crystal structures of sampatrilat and sampatrilat-Asp in complex with human ACE - a molecular basis for domain selectivity.
Gyles E Cozier, Sylva L Schwager, Rajni K Sharma, Kelly Chibale, Edward D Sturrock, K Ravi Acharya. FEBS J 2018
18
22

Vasopeptidase inhibitors.
M A Weber. Lancet 2001
94
8

Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase.
J A Robl, C Q Sun, J Stevenson, D E Ryono, L M Simpkins, M P Cimarusti, T Dejneka, W A Slusarchyk, S Chao, L Stratton,[...]. J Med Chem 1997
135
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.